DA
Therapeutic Areas
SPARC Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SCD-044 | Moderate to Severe Dry Eye Disease | Phase 3 |
| Xelpros™ (latanoprost) | Glaucoma | Approved |
| BromSite® (bromfenac) | Post-operative inflammation and pain following cataract surgery | Approved |
| CEQUA® (cyclosporine) | Dry Eye Disease | Approved |
| TAC-302 | Diabetic Peripheral Neuropathic Pain | Phase 2 |
| SCD-105 | Psoriasis | Phase 2 |
| SCD-117 | Atopic Dermatitis | Phase 2 |
| SCD-684 | Ophthalmic inflammation | Pre-clinical |
Leadership Team at SPARC
DS
Dilip Shanghvi
Promoter and Key Shareholder
AR
Anil Raghavan
Managing Director and CEO
KG
Kirti Ganorkar
Executive Director and CEO (Designate)
SV
Sudhir Valia
Director
SD
Sailesh Desai
Director
UB
Uday Baldota
Chief Financial Officer
DV
Dr. Vikas Saxena
Head - Clinical Development
MS
M. S. Iyer
Company Secretary and Compliance Officer